Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

Benzinga Newsdesk www.benzinga.com Positive 91.9%

Neg 0% Neu 0% Pos 91.9%

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $152 to $155.